AU2018375340B2 - Anti-TrkB monoclonal antibodies and methods of use - Google Patents

Anti-TrkB monoclonal antibodies and methods of use

Info

Publication number
AU2018375340B2
AU2018375340B2 AU2018375340A AU2018375340A AU2018375340B2 AU 2018375340 B2 AU2018375340 B2 AU 2018375340B2 AU 2018375340 A AU2018375340 A AU 2018375340A AU 2018375340 A AU2018375340 A AU 2018375340A AU 2018375340 B2 AU2018375340 B2 AU 2018375340B2
Authority
AU
Australia
Prior art keywords
trkb
antibody
antigen
binding fragment
antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2018375340A
Other languages
English (en)
Other versions
AU2018375340A1 (en
Inventor
Susan D. Croll
Min Gao
Ying Hu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Regeneron Pharmaceuticals Inc
Original Assignee
Regeneron Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharmaceuticals Inc filed Critical Regeneron Pharmaceuticals Inc
Publication of AU2018375340A1 publication Critical patent/AU2018375340A1/en
Application granted granted Critical
Publication of AU2018375340B2 publication Critical patent/AU2018375340B2/en
Priority to AU2026200583A priority Critical patent/AU2026200583A1/en
Priority to AU2026200616A priority patent/AU2026200616A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AU2018375340A 2017-11-30 2018-11-28 Anti-TrkB monoclonal antibodies and methods of use Active AU2018375340B2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2026200583A AU2026200583A1 (en) 2017-11-30 2026-01-28 Anti-TrkB monoclonal antibodies and methods of use
AU2026200616A AU2026200616A1 (en) 2017-11-30 2026-01-28 Anti-TrkB monoclonal antibodies and methods of use

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762592657P 2017-11-30 2017-11-30
US62/592,657 2017-11-30
PCT/US2018/062863 WO2019108662A1 (en) 2017-11-30 2018-11-28 Anti-trkb monoclonal antibodies and methods of use

Related Child Applications (2)

Application Number Title Priority Date Filing Date
AU2026200583A Division AU2026200583A1 (en) 2017-11-30 2026-01-28 Anti-TrkB monoclonal antibodies and methods of use
AU2026200616A Division AU2026200616A1 (en) 2017-11-30 2026-01-28 Anti-TrkB monoclonal antibodies and methods of use

Publications (2)

Publication Number Publication Date
AU2018375340A1 AU2018375340A1 (en) 2020-05-07
AU2018375340B2 true AU2018375340B2 (en) 2025-10-30

Family

ID=64665125

Family Applications (3)

Application Number Title Priority Date Filing Date
AU2018375340A Active AU2018375340B2 (en) 2017-11-30 2018-11-28 Anti-TrkB monoclonal antibodies and methods of use
AU2026200583A Pending AU2026200583A1 (en) 2017-11-30 2026-01-28 Anti-TrkB monoclonal antibodies and methods of use
AU2026200616A Pending AU2026200616A1 (en) 2017-11-30 2026-01-28 Anti-TrkB monoclonal antibodies and methods of use

Family Applications After (2)

Application Number Title Priority Date Filing Date
AU2026200583A Pending AU2026200583A1 (en) 2017-11-30 2026-01-28 Anti-TrkB monoclonal antibodies and methods of use
AU2026200616A Pending AU2026200616A1 (en) 2017-11-30 2026-01-28 Anti-TrkB monoclonal antibodies and methods of use

Country Status (18)

Country Link
US (3) US11066474B2 (https=)
EP (1) EP3717514A1 (https=)
JP (2) JP7438937B2 (https=)
KR (1) KR20200090779A (https=)
CN (2) CN111372949B (https=)
AU (3) AU2018375340B2 (https=)
BR (1) BR112020006976A2 (https=)
CA (1) CA3083452A1 (https=)
CL (3) CL2020000855A1 (https=)
CO (1) CO2020004075A2 (https=)
EA (1) EA202090966A1 (https=)
IL (1) IL273538B2 (https=)
MA (1) MA51207A (https=)
MX (3) MX2020003550A (https=)
MY (1) MY203247A (https=)
PH (1) PH12020550409A1 (https=)
SG (1) SG11202002665UA (https=)
WO (1) WO2019108662A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10793634B2 (en) 2017-06-09 2020-10-06 Boehringer Ingelheim International Gmbh Anti-TrkB antibodies
WO2019108662A1 (en) * 2017-11-30 2019-06-06 Regeneron Pharmaceuticals, Inc. Anti-trkb monoclonal antibodies and methods of use
IL310006A (en) * 2017-11-30 2024-03-01 Regeneron Pharma Non-human animals containing a humanized TRKB locus
JP7524158B2 (ja) * 2019-03-04 2024-07-29 公益財団法人東京都医学総合研究所 Ｔｒｋ断片をコードする核酸構築物、及びその利用
US12559560B2 (en) * 2020-01-30 2026-02-24 Fred Hutchinson Cancer Center Antibody-based compositions for targeting tropomyosin receptor kinase B (TrkB) isoforms
WO2023125485A1 (en) * 2021-12-28 2023-07-06 4B Technologies (Beijing) Co., Limited TrkB ANTIBODY AND APPLICATION THEREOF
TW202342494A (zh) 2022-03-30 2023-11-01 日商肽夢想股份有限公司 具有TrkB結合活性之肽複合物
CN120665203B (zh) * 2025-06-18 2026-03-27 广东优赛生物医药科技有限公司 一种药物组合物及其在治疗中枢性肥胖中的应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100196390A1 (en) * 2009-02-02 2010-08-05 Rinat Neuroscience Corp. Agonist anti-trkb monoclonal antibodies

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5877016A (en) 1994-03-18 1999-03-02 Genentech, Inc. Human trk receptors and neurotrophic factor inhibitors
US6225282B1 (en) 1996-01-05 2001-05-01 Genentech, Inc. Treatment of hearing impairments
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
WO2006133164A2 (en) 2005-06-06 2006-12-14 Wyeth Anti-trkb monoclonal antibodies and uses thereof
EP1988923A1 (en) * 2006-02-02 2008-11-12 Rinat Neuroscience Corp. Methods for treating unwanted weight loss or eating disorders by administering a trkb agonist
EP1988920A1 (en) 2006-02-02 2008-11-12 Rinat Neuroscience Corp. Methods for treating obesity by administering a trkb antagonist
ES2398076T3 (es) 2006-06-02 2013-03-13 Regeneron Pharmaceuticals, Inc. Anticuerpos de alta afinidad contra el receptor de IL-6 humano
WO2008058127A2 (en) 2006-11-09 2008-05-15 Irm Llc Agonist trkb antibodies and uses thereof
CA2672750A1 (en) * 2006-12-20 2008-07-03 Rinat Neuroscience Corporation Trkb agonists for treating autoimmune disorders
WO2009048605A1 (en) 2007-10-11 2009-04-16 Biogen Idec Ma Inc. Methods for treating pressure induced optic neuropathy, preventing neuronal degeneration and promoting neuronal cell, survival via administration of lingo-1 antagonists and trkb agonists
CA2712298C (en) 2008-01-17 2015-11-24 Irm Llc Improved anti-trkb antibodies
WO2011103667A1 (en) 2010-02-26 2011-09-01 6452728 Canada Inc. Agonistic antibodies to trkb receptors and uses thereof
GB2491106A (en) 2011-05-18 2012-11-28 Univ Basel Antibodies against tropomyosin-related kinase B receptors
US10080745B2 (en) 2013-11-25 2018-09-25 The Regents Of The University Of California Santa Cruz Piericidin bacterial inhibitors
ES2936810T3 (es) 2014-05-16 2023-03-22 Pfizer Anticuerpos biespecíficos con interfaces CH1-CL de ingeniería
CA2993645A1 (en) 2015-07-28 2017-02-02 Otonomy, Inc. Trkb or trkc agonist compositions and methods for the treatment of otic conditions
CA3005491A1 (en) 2015-11-17 2017-05-26 Glaxosmithkline Intellectual Property Development Limited Binding agonists for treatment of neurological and other disorders
JP2019517787A (ja) * 2016-05-03 2019-06-27 ザ スクリプス リサーチ インスティテュート 神経変性障害の処置のためのＴｒｋＢアゴニスト抗体
US9914781B1 (en) 2016-11-08 2018-03-13 Glaxosmithkline Intellectual Property Development Limited Binding agonist for treatment of neurological and other disorders
EP4095161A1 (en) * 2017-03-15 2022-11-30 Tsinghua University Novel anti-trkb antibodies
WO2019108662A1 (en) * 2017-11-30 2019-06-06 Regeneron Pharmaceuticals, Inc. Anti-trkb monoclonal antibodies and methods of use

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100196390A1 (en) * 2009-02-02 2010-08-05 Rinat Neuroscience Corp. Agonist anti-trkb monoclonal antibodies

Also Published As

Publication number Publication date
BR112020006976A2 (pt) 2020-10-13
CL2024002614A1 (es) 2025-01-24
AU2026200583A1 (en) 2026-02-19
MX2025001445A (es) 2025-03-07
EP3717514A1 (en) 2020-10-07
JP7438937B2 (ja) 2024-02-27
CL2020000855A1 (es) 2020-07-31
JP2024016204A (ja) 2024-02-06
US20240309100A1 (en) 2024-09-19
CN121181700A (zh) 2025-12-23
KR20200090779A (ko) 2020-07-29
IL273538B2 (en) 2024-10-01
US20220411515A1 (en) 2022-12-29
JP2021507677A (ja) 2021-02-25
US12037401B2 (en) 2024-07-16
IL273538B1 (en) 2024-06-01
SG11202002665UA (en) 2020-04-29
AU2018375340A1 (en) 2020-05-07
EA202090966A1 (ru) 2020-08-26
MA51207A (fr) 2020-10-07
CA3083452A1 (en) 2019-06-06
IL273538A (en) 2020-05-31
NZ763618A (en) 2025-05-02
AU2026200616A1 (en) 2026-02-19
MX2025001444A (es) 2025-03-07
WO2019108662A1 (en) 2019-06-06
CN111372949B (zh) 2026-02-03
MX2020003550A (es) 2020-08-03
MY203247A (en) 2024-06-19
CO2020004075A2 (es) 2020-08-31
CN111372949A (zh) 2020-07-03
US20190161551A1 (en) 2019-05-30
PH12020550409A1 (en) 2021-04-12
US11066474B2 (en) 2021-07-20
CL2024002612A1 (es) 2025-01-24

Similar Documents

Publication Publication Date Title
JP7589200B2 (ja) 抗アクチビンａ抗体及びその使用
US12037401B2 (en) Anti-TrkB monoclonal antibodies and methods of use
RS55054B1 (sr) Ljudska antitela visokog afiniteta prema ljudskom angiopoietinu-2
EA044580B1 (ru) Моноклональные анти-trkb антитела и способы их применения
HK40081330A (en) Anti-activin a antibodies and uses thereof
HK40030562A (en) Anti-activin a antibodies and uses thereof
HK40081535A (en) Anti-activin a antibodies and uses thereof
NZ716854B2 (en) Anti-activin a antibodies and uses thereof
HK1225322B (en) Anti-activin a antibodies and uses thereof
NZ754959B2 (en) Anti-activin a antibodies and uses thereof

Legal Events

Date Code Title Description
DA2 Applications for amendment section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 28 JAN 2026